Injection route matters for peptides, but effects vary by molecule

Why does the tissue you inject into change absorption?

Fat and muscle differ in blood flow, capillary density, and how much of their fluid drainage runs through blood vessels rather than lymphatic vessels.

Muscle is heavily perfused with blood and drains largely into local capillaries. Fat has lower blood flow and a proportionally larger role for lymphatic drainage. That slower vessel network, in other tissues, preferentially picks up larger particles that blood capillary walls tend to exclude by size, as seen with dietary fat absorption in the gut ^[7].

A small peptide that diffuses easily into blood capillaries may not care much which tissue it lands in. A larger peptide, or one broken down by local enzymes before it clears the injection site, can behave very differently depending on whether it has to detour through lymph first.

Which absorption pathway a molecule is forced to use is the pharmacological reason route gets discussed at all. The pathway is set by the tissue's local blood flow and vessel permeability, not by comfort, needle length, or which method feels more serious. Needle length determines injection depth covers how the equipment decides which tissue a dose lands in.

Does intramuscular injection deliver more peptide than subcutaneous?

Not necessarily. In the clearest head-to-head comparison, recombinant glucagon reached similar total blood exposure by both routes while peaking higher intramuscularly ^[4].

In a randomized crossover study, total exposure measured as area under the concentration curve was 5.87 ng·h/mL subcutaneous versus 6.63 ng·h/mL intramuscular, a difference that did not reach statistical significance. Peak concentration did differ significantly, at 7.94 versus 9.12 ng/mL (p < 0.05) ^[4].

The glucagon study is the clearest illustration of the rate-versus-extent distinction. Both routes got a similar total amount of hormone into blood over time, and intramuscular got there faster and higher. Intramuscular versus subcutaneous peptide injection works through what that distinction means in practice.

Does the injection site within subcutaneous fat matter?

Site changes timing more than total absorption, judging by insulin analog research, which mostly compares subcutaneous sites against each other rather than against intramuscular.

Ultra rapid lispro showed roughly 65% absolute bioavailability whether it was injected into abdomen, upper arm or thigh fat, with time to half-maximal concentration around 10 minutes at all three sites ^[2].

A needle-free jet injector study of insulin aspart found measurable differences in skin thickness by site, abdomen 2.45 mm versus thigh 1.93 mm (p = 0.014), that tracked with differences in absorption curves ^[3].

Insulin aspart injected into deltoid, abdomen and thigh produced faster peak glucose infusion rates than regular human insulin at every site, showing that formulation and site both move the curve, independent of each other ^[5].

Is there a fixed ratio between subcutaneous and intramuscular delivery?

No. Pasireotide shows the ratio moving with dose and formulation, not just route.

A subcutaneous depot version compared against an intramuscular long-acting release version produced relative bioavailability estimates ranging from 0.517 to 1.15 depending on dose. Against an immediate-release subcutaneous comparator, the range was 0.752 to 1.68 ^[1].

No single "subcutaneous delivers X% of intramuscular" figure holds even within one peptide across its different preparations.

Do these route studies apply to the peptides people inject?

No. The studied molecules are insulin analogs, glucagon and pasireotide, not the peptides most commonly discussed outside a pharmaceutical trial setting.

Those molecules are either small hormones with decades of regulatory-grade study behind them or engineered depot formulations built specifically to control their own release. They establish the mechanism and the range of possible outcomes, from no meaningful difference to meaningfully different depending on dose and formulation. They do not establish a number for any specific unstudied peptide.

Why can't animal bioavailability data settle the question?

Species alone can move a bioavailability figure threefold. A widely cited pharmacokinetics paper on BPC-157 reported absolute intramuscular bioavailability of roughly 14% to 19% in rats versus roughly 45% to 51% in beagle dogs, for the identical peptide given by the identical route.

No human bioavailability figure for BPC-157 by any route is established. If species alone can move a number that much, extrapolating an animal figure to a human dosing decision is not a conservative assumption, and extrapolating a route effect measured in one peptide onto an unrelated one is less conservative still. It is an unverified guess with a number attached to make it look verified. BPC-157 half-life claims trace the same extrapolation problem through a different parameter.

Does injection site damage change absorption?

Repeated injection into the same fat site is associated with lipohypertrophy, a buildup of fat and fibrous tissue linked to unpredictable insulin release from that site ^[6].

One large cohort found lipohypertrophy in 59% of insulin-treated patients with type 2 diabetes ^[6]. A route effect measured in healthy, untreated tissue in a trial may not hold in someone's actual, repeatedly injected fat. Injection site lumps and rotation covers how that tissue change develops.

What is still unknown about injection route for peptides?

For the great majority of peptides discussed in clinics and online communities, nobody has published a controlled subcutaneous-versus-intramuscular comparison in humans.

No general rule says intramuscular delivers more peptide into blood than subcutaneous. The relationship is true for some molecules, roughly equal for others, and reversed by dose or formulation in at least one studied case ^[1]⁠^[4].

Changing injection route without a peptide-specific human pharmacokinetic study means changing an unmeasured variable and hoping the dose still means the same thing. Route matters, sometimes a lot, and for most peptides discussed outside a trial, the size and direction of that effect has never been measured.